文献速递冠心病瓣膜病与结构性心脏病

富含半胱氨酸血管生成诱导因子61:急性心肌损伤的新型可溶性生物标志物,改善急性冠脉综合征风险分层

Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes.
PubMed 文献 · Eur Heart J · 2017-01-01

本研究通过基因表达谱识别Cyr61为急性冠脉综合征(ACS)相关新型生物标志物,并在小鼠缺血再灌注模型及ACS、稳定冠心病和肥厚型梗阻性心肌病人群中评估其诊断和预后价值。结果显示Cyr61在ST段抬高型心肌梗死患者中显著升高,且快速释放,加入GRACE评分可改善30天和1年全因死亡风险分层,但在基于人群的病例对照队列中与不良结局无关。

要点

  • Cyr61在STEMI患者中显著升高,且不依赖冠脉血栓是否存在。
  • Cyr61在冠脉间隔支闭塞后快速释放,反映早期心肌损伤。
  • Cyr61加入GRACE评分可改善ACS患者30天和1年全因死亡风险分层。

核心结论

  • Cyr61是一种反映心肌损伤的新型早期生物标志物,可改善ACS患者的风险分层。

研究设计与样本

  • 基于基因表达谱识别Cyr61,并在小鼠缺血再灌注模型及ACS(n=2168)、稳定CAD(n=53)和HOCM(n=15)患者中评估。
  • 另在基于人群的病例对照队列(n=362)中验证Cyr61与不良结局的关联。

主要发现

  • ACS患者冠脉血栓中Cyr61基因转录本较外周单个核细胞高度上调。
  • 小鼠缺血再灌注模型中心肌Cyr61表达较对照组显著增加。
  • STEMI患者Cyr61水平显著高于NSTEMI/UA或稳定CAD患者,无论是否存在冠脉血栓。
  • HOCM患者经冠状动脉间隔支消融术后Cyr61快速释放。
  • Cyr61加入GRACE评分改善30天全因死亡风险分层(C统计量0.88至0.89,P=0.001)和1年(C统计量0.77至0.80,P<0.001),与高敏肌钙蛋白T相当。

关键数值与推荐

  • Cyr61加入GRACE评分后30天全因死亡C统计量从0.88升至0.89(P=0.001),1年从0.77升至0.80(P<0.001)。
  • 高敏肌钙蛋白T加入GRACE评分后30天C统计量从0.88升至0.89(P<0.001),1年从0.77升至0.79(P<0.001)。

临床怎么用

  • Cyr61可作为ACS早期心肌损伤的生物标志物,辅助GRACE评分进行风险分层。
  • 在疑似ACS患者中,Cyr61水平升高提示需更积极的风险评估和管理。

局限性

  • 在基于人群的病例对照队列(n=362)中,Cyr61与不良结局无关。
  • 研究未报告Cyr61的临床决策阈值或治疗指导价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: We aimed to identify a novel biomarker involved in the early events leading to an acute coronary syndrome (ACS) and evaluate its role in diagnosis and risk stratification. METHODS AND RESULTS: Biomarker identification was based on gene expression profiling. In coronary thrombi of ACS patients, cysteine-rich angiogenic inducer 61 (Cyr61, CCN1) gene transcripts were highly up-regulated compared with peripheral mononuclear cells. In a murine ischaemia-reperfusion model (I/R), myocardial Cyr61 expression was markedly increased compared with the controls. Cyr61 levels were determined in human serum using an enzyme-linked immunosorbent assay. Cohorts of ACS (n = 2168) referred for coronary angiography, stable coronary artery disease (CAD) (n = 53), and hypertrophic obstructive cardiomyopathy (HOCM) patients (n = 15) served to identify and evaluate the diagnostic and prognostic performance of the biomarker. Cyr61 was markedly elevated in ST-elevation myocardial infarction patients compared with non-ST-elevation myocardial infarction/unstable angina or stable CAD patients, irrespective of whether coronary thrombi were present. Cyr61 was rapidly released after occlusion of a septal branch in HOCM patients undergoing transcoronary ablation of septal hypertrophy. Cyr61 improved risk stratification for all-cause mortality when added to the reference GRACE risk score at 30 days (C-statistic 0.88 to 0.89, P = 0.001) and 1 year (C-statistic 0.77 to 0.80, P < 0.001) comparable to high-sensitivity troponin T (30 days: 0.88 to 0.89, P < 0.001; 1 year: 0.77 to 0.79, P < 0.001). Similar results were obtained for the composite endpoint of all-cause mortality or myocardial infarction. Conversely, in a population-based case-control cohort (n = 362), Cyr61 was not associated with adverse outcome. CONCLUSION: Cyr61 is a novel early biomarker reflecting myocardial injury that improves risk stratification in ACS patients.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Klingenberg R, Aghlmandi S, Liebetrau C, et al. Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. Eur Heart J. 2017. PMID: 29155984. doi:10.1093/eurheartj/ehx640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。